In Brief: Strong Results Advance DualityBio/BioNTech’s B7H3 ADC Into Phase III CRPC Trial

 
• By Dexter Jie Yan
  
DualityBio touted DB-1311 as the first B7H3-targeting ADC that has demonstrated strong results in a mCRPC population that has received Novartis’s Pluvicto. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D